Liver Transplant Evaluation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Liver transplant evaluation is a comprehensive, structured multi-disciplinary workup designed to determine whether a patient with end-stage liver disease (ESLD) or acute liver failure (ALF) is medically, surgically, and psychosocially suitable for liver transplantation. The evaluation is performed by a transplant team that typically includes hepatologists, transplant surgeons, cardiologists, pulmonologists, nephrologists, psychiatrists or psychologists, social workers, financial counselors, and transplant coordinators.

The central quantitative tool used in the evaluation and subsequent organ allocation is the Model for End-Stage Liver Disease (MELD) score, which uses three objective laboratory values to predict 90-day mortality without transplantation:

• MELD formula: 3.78 × ln(serum bilirubin mg/dL) + 11.2 × ln(INR) + 9.57 × ln(serum creatinine mg/dL) + 6.43
• MELD-Na (sodium-adjusted): incorporates serum sodium, shown to improve waitlist mortality prediction. Formula: MELD + 1.32 × (137 − Na) − [0.033 × MELD × (137 − Na)]. Used by UNOS since 2016.
• MELD scores range from 6 to 40. A score ≥15 is the accepted threshold at which transplant survival benefit outweighs the risks of surgery and lifelong immunosuppression.

The evaluation process also establishes baseline organ function, identifies comorbidities that require optimisation before listing, determines contraindications, and ensures the patient has an adequate social support network for post-transplant care.

Liver transplantation is indicated for patients with irreversible liver failure not amenable to medical therapy. Major indications include:

Chronic Liver Disease (Cirrhosis)

• Alcohol-related liver disease (ALD): Largest single indication in Western countries. Patients must demonstrate minimum 6 months of alcohol abstinence and engage with addiction support.
• Non-alcoholic steatohepatitis (MASH/NASH): Rapidly growing indication, often complicated by metabolic syndrome, obesity, and cardiovascular disease.
• Viral hepatitis: Hepatitis B (with maintained viral suppression on antiviral therapy) and Hepatitis C (cured with DAAs; excellent post-transplant outcomes).
• Primary sclerosing cholangitis (PSC): Progressive fibro-obliterative biliary disease, often associated with inflammatory bowel disease.
• Primary biliary cholangitis (PBC): Autoimmune cholestatic disease refractory to ursodeoxycholic acid or obeticholic acid.
• Autoimmune hepatitis (AIH): Refractory to or complicated by immunosuppressive therapy.
• Wilson disease, haemochromatosis, alpha-1 antitrypsin deficiency: Metabolic/genetic liver diseases causing cirrhosis.

Hepatocellular Carcinoma (HCC)

• Patients within Milan criteria (single tumour ≤5 cm or up to 3 tumours each ≤3 cm, no vascular invasion, no extrahepatic disease) have 5-year post-transplant survival >70% and a low recurrence rate.
• Extended criteria (UCSF, Up-to-7) may be considered at specialised centres.
• Locoregional therapy (TACE, ablation) is used as a bridge to transplant to prevent tumour progression beyond Milan criteria.

Acute Liver Failure (ALF)

• Paracetamol (acetaminophen) toxicity: King's College Criteria used to guide urgent listing.
• Drug-induced liver injury (DILI), viral hepatitis, Wilson disease presenting as ALF, indeterminate ALF.
• ALF patients may receive super-urgent (Status 1A) listing and bypass standard MELD allocation.

Acute-on-Chronic Liver Failure (ACLF)

• ACLF is a distinct syndrome of acute decompensation (ascites, encephalopathy, infection) superimposed on known cirrhosis with organ failures. ACLF Grade 2–3 carries high short-term mortality and may warrant urgent evaluation.

Listing for transplantation requires meeting both the benefit threshold and the absence of absolute contraindications.

Listing Criteria

• MELD score ≥15 or MELD-Na ≥15 (benefit-to-risk threshold)
• Child-Pugh class C cirrhosis (score ≥10) or class B with complications refractory to medical therapy
• Complications of portal hypertension refractory to endoscopic/pharmacological therapy: recurrent variceal haemorrhage, refractory ascites, spontaneous bacterial peritonitis, hepatorenal syndrome (HRS), hepatic encephalopathy
• Hepatopulmonary syndrome (HPS) with PaO₂ <60 mmHg on room air (MELD exception points granted)
• HCC within Milan criteria (MELD exception points granted to account for tumour progression risk)

Absolute Contraindications

• Active alcohol or illicit substance use: Minimum 6-month abstinence is required. Patients must be enrolled in addiction treatment and demonstrate psychosocial stability. Urine/hair drug screens are used for monitoring.
• Active malignancy outside Milan criteria or extrahepatic malignancy with insufficient disease-free interval (typically 2–5 years depending on tumour type)
• Severe, irreversible cardiopulmonary disease that precludes major surgery: LVEF <40% unresponsive to optimisation, portopulmonary hypertension (PoPH) with mean PAP >50 mmHg unresponsive to vasodilators, severe COPD
• Uncontrolled systemic infection or sepsis at time of transplant
• Anatomical impossibility of hepatic reconstruction
• Irreversible neurological injury in ALF (cerebral oedema with herniation)

Relative Contraindications (Centre-Specific)

• Age >70 years with significant comorbidities
• Severe obesity (BMI >40) — weight loss programme may be required
• HIV (no longer an absolute contraindication at experienced centres with controlled viral load)
• Prior major abdominal surgery (increases technical complexity)
• Lack of adequate social support

The evaluation is systematic and multi-organ, ensuring all potential surgical risks are identified and modifiable factors optimised before listing.

Cardiac Evaluation

Liver transplant surgery carries a perioperative cardiac mortality risk of 1–3%. All candidates undergo:

• Resting echocardiography: Assesses LVEF, wall motion, valvular disease, and estimated right heart pressures (pulmonary hypertension screening).
• Dobutamine stress echocardiography (DSE): Preferred pharmacological stress test in cirrhosis (adenosine and exercise stress less reliable). Identifies inducible ischaemia and contractile reserve.
• Coronary angiography: Performed in patients with DSE abnormalities, known CAD, or multiple cardiac risk factors. Percutaneous coronary intervention (PCI) or CABG may be required before listing.
• 12-lead ECG and 24-hour Holter where arrhythmia is suspected.

Pulmonary Evaluation

• Hepatopulmonary syndrome (HPS): Intrapulmonary vascular dilatation causing hypoxaemia (PaO₂ <80 mmHg). Diagnosed by contrast-enhanced echocardiography (bubble study) showing late atrial opacification. HPS resolves post-transplant; patients receive MELD exception points.
• Portopulmonary hypertension (PoPH): Pulmonary arterial hypertension in the context of portal hypertension. Right heart catheterisation is the gold standard. Mild-moderate PoPH (mean PAP 25–50 mmHg) may be managed with pulmonary vasodilators (sildenafil, macitentan, epoprostenol) to allow transplant listing. Severe PoPH (mean PAP >50 mmHg) is generally an absolute contraindication.
• Chest CT and pulmonary function tests (spirometry, DLCO) for baseline assessment and surgical risk.

Renal and Metabolic Evaluation

• Estimated GFR (eGFR) by CKD-EPI or CKD-EPI-Cr/Cys cystatin C equation — distinguishes true CKD from hepatorenal syndrome (HRS), which is functional and reversible post-transplant.
• 24-hour urine protein quantification. Patients with CKD may be considered for simultaneous liver-kidney (SLK) transplantation per UNOS SLK policy (sustained AKI on dialysis ≥6 weeks or eGFR <25 mL/min for >90 days).
• Nutritional assessment: body composition, handgrip strength (sarcopenia is an independent predictor of post-transplant mortality), dietitian review.

Laboratory and Imaging Workup

• Full blood count, coagulation screen (PT/INR), liver function tests, renal function, electrolytes, lipids, glucose
• Viral serologies: HIV, Hepatitis B (HBsAg, HBcAb, HBsAb), Hepatitis C (HCV RNA), CMV, EBV, HSV, VZV, Toxoplasma
• Autoimmune markers: ANA, ANCA, AMA, ASMA, anti-LKM (to classify underlying liver disease)
• Tumour markers: AFP (hepatocellular carcinoma), CA 19-9 (cholangiocarcinoma screening in PSC patients), CEA
• Cross-sectional imaging: triple-phase CT or MRI of abdomen to assess hepatic vasculature, portal vein patency, portal vein thrombosis extent, tumour burden, and biliary anatomy
• Upper GI endoscopy: assess varices (band ligation if high-risk), portal hypertensive gastropathy
• Bone densitometry (DEXA scan): metabolic bone disease is common in cirrhosis

Psychosocial and Addiction Evaluation

• Formal psychiatric assessment: screen for depression, anxiety, cognitive impairment, personality disorders
• Addiction specialist evaluation: confirm abstinence, risk of recidivism, engagement with treatment programmes (AA, SMART Recovery)
• Social work assessment: housing stability, financial resources, insurance coverage, reliable caregiver availability
• Financial counselling: pre-authorisation, hospital costs, post-transplant medication costs (tacrolimus, MMF: $500–1,500/month)

Living Donor Liver Transplant (LDLT) Evaluation

When a willing living donor is available, a separate rigorous evaluation of the donor is undertaken:

• Volumetric CT to assess liver volume: the donor must retain a future liver remnant (FLR) of ≥30% of total liver volume
• Right lobe donation (segments 5–8) provides a larger graft but carries a donor mortality of approximately 0.5% and morbidity of 15–20%
• Left lobe or left lateral segment donation (segments 2–3) is safer (≤0.1% mortality) and used for paediatric recipients
• Donor work-up: liver biopsy if hepatic steatosis >10% on imaging, bile duct anatomy by MRCP
• LDLT typically achieves equivalent or superior outcomes to deceased donor liver transplant (DDLT) at experienced centres

Completing a thorough transplant evaluation early in the course of end-stage liver disease confers several evidence-based advantages:

• Survival benefit: For patients with MELD ≥15, liver transplantation provides a statistically significant survival advantage over continued medical therapy. One-year post-transplant survival exceeds 90% at experienced centres; five-year survival is approximately 75%.
• Waitlist optimisation: Early listing ensures the patient accumulates waitlist time and MELD exception points (for HCC, HPS), maximising their position when an organ becomes available.
• Bridge therapy: Transjugular intrahepatic portosystemic shunt (TIPS) can be placed as a bridge to transplant to control refractory ascites or variceal haemorrhage, reducing decompensation events while awaiting an organ.
• Comorbidity optimisation: Identification of cardiac disease, malnutrition, or PoPH allows targeted treatment to expand candidacy.
• Quality of life: Patients who undergo transplantation for cirrhosis report major improvements in fatigue, hepatic encephalopathy, ascites, and overall health-related quality of life.
• HCC cure: Transplantation within Milan criteria offers the only curative option for HCC in the setting of underlying cirrhosis, with 5-year recurrence rates of <15%.

The evaluation process itself carries minimal direct procedural risk, but several important considerations apply:

• Coronary angiography: Small risk of contrast nephropathy, vascular access complications, and contrast allergy. Pre-hydration and N-acetylcysteine may be used in patients with borderline renal function.
• Declining candidacy: Patients discovered to have absolute contraindications (uncontrolled malignancy, severe PoPH) will not be listed. This necessitates careful palliative planning and goals-of-care discussions.
• Psychosocial risks: Denial of listing due to psychosocial concerns (inadequate support, continued substance use) can be distressing; structured referral to social services and addiction programmes is essential.
• Waitlist mortality: MELD score ≥20 carries a 6-month waitlist mortality of approximately 10–15%. Organ shortage remains the principal limitation; approximately 1,500 patients die on the US waitlist annually.
• Waiting period complications: Progressive decompensation, infections (SBP, bacteraemia), HRS, hepatic encephalopathy, and HCC progression can occur while awaiting a donor organ.

Once listed, patients require structured follow-up to maintain waitlist eligibility, manage complications, and detect changes in clinical status:

• MELD recalculation: MELD is recalculated at fixed intervals based on current score (every 7 days for MELD ≥25; every 30 days for MELD 19–24; every 90 days for MELD 11–18; every 12 months for MELD ≤10). Laboratory values must remain current for active status.
• HCC surveillance (bridge therapy monitoring): Patients with HCC on the waitlist undergo cross-sectional imaging every 3–6 months to confirm tumour stability within Milan criteria. Locoregional therapy (TACE, microwave ablation, Y-90 radioembolisation) is repeated if progression is detected.
• Nutritional support: Regular dietitian review; high-protein diet (1.2–1.5 g/kg/day), late-evening snack to prevent fasting catabolism; BCAA supplementation if indicated.
• TIPS as a bridge: Refractory ascites or recurrent variceal haemorrhage may prompt elective TIPS insertion to stabilise the patient and reduce hospitalisation while awaiting transplant. TIPS does not preclude subsequent transplantation.
• Repeat cardiac assessment: Annual echocardiography or sooner if clinical status changes, to ensure cardiac eligibility is maintained.
• Abstinence monitoring: Regular urine/hair/ethyl glucuronide (EtG) drug and alcohol screens for patients with prior alcohol or substance use disorders.
• Transplant coordinator contact: Patients must be reachable 24/7 and able to present to the transplant centre within 4–6 hours of organ offer notification.

Treatment costs for Liver Transplant Evaluation vary significantly by procedure complexity, healthcare system, and geographic location. In India — the leading global medical tourism destination — major procedures cost 60–85% less than comparable treatment in the USA or UK while maintaining equivalent or superior clinical outcomes at NABH- or JCI-accredited facilities. Consultation and diagnostic workup: $30–200 India vs $500–3,000 USA. Inpatient procedures: $1,000–10,000 India vs $10,000–80,000 USA. Medications and ongoing management: generic drugs available in India at 80–95% lower cost than branded equivalents in the USA. Follow-up imaging and laboratory monitoring: 70–85% cost savings in India. Medical tourism packages (including treatment, accommodation, and local logistics support) are offered by major Indian hospital groups (Apollo, Fortis, Medanta, Narayana Health, Manipal Hospitals). For patients from high-income countries, medical tourism to India, Thailand, or Turkey for elective procedures can achieve savings of $10,000–200,000 per episode while accessing care from internationally trained specialists.

For patients who are not candidates for transplantation, or who are awaiting listing, several management strategies can extend life and improve quality of life:

• Transjugular intrahepatic portosystemic shunt (TIPS): An interventional radiology procedure that creates a low-resistance channel between the portal and hepatic veins, decompressing portal hypertension. TIPS is highly effective for refractory ascites (eliminates ascites in 70–80%) and prevention of variceal rebleeding. It does not treat the underlying liver disease and may worsen hepatic encephalopathy.
• Medical management of complications: Diuretics (spironolactone + furosemide) for ascites, non-selective beta-blockers (propranolol, carvedilol) for portal hypertension, rifaximin + lactulose for hepatic encephalopathy, prophylactic norfloxacin for SBP in high-risk patients, terlipressin + albumin for hepatorenal syndrome.
• Locoregional therapy for HCC: TACE, thermal ablation, Y-90 radioembolisation, stereotactic body radiotherapy (SBRT) as bridge or as definitive palliation for patients not suitable for transplant or resection.
• Liver resection: In patients with compensated cirrhosis (Child-Pugh A, MELD <10) and HCC, hepatic resection offers potential cure without transplantation, with the option of salvage transplant for recurrence.
• Palliative and supportive care: For patients with MELD >30 who are not candidates for transplant, early palliative care integration improves symptom management and end-of-life planning. Referral to specialist palliative hepatology services is recommended.